Squarepoint
CTXR icon

Squarepoint’s Citius Pharmaceuticals CTXR Stock Holding History

Squarepoint’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,983
Closed -$90.9K – 4581
2025
Q1 		$90.9K Buy
60,983
+11,315
+23% +$27.1K ﹤0.01% 4241
2024
Q4 		$199K Buy
49,668
+23,293
+88% +$157K ﹤0.01% 4478
2024
Q3 		$330K Buy
+26,375
New +$444K ﹤0.01% 3384
2023
Q2 		– Sell
-2,941
Closed -$86K – 3634
2023
Q1 		$86K Buy
+2,941
New +$84.8K ﹤0.01% 2993
2021
Q4 		– Sell
-400
Closed -$20K – 3212
2021
Q3 		$20K Buy
+400
New +$20.1K ﹤0.01% 2822

Other funds holding CTXR

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Squarepoint's CTXR Position: Q2 2025 in Review

Squarepoint sold out of Citius Pharmaceuticals (CTXR) in Q2 2025, closing a stake of 60,983 shares — an estimated $90.9K sold.

Squarepoint first reported a position in CTXR in Q3 2021 and held it in 5 quarters. The position peaked at $330K in Q3 2024. 31 funds tracked by Wall St. Rank hold CTXR as of Q2 2025.

  • Squarepoint reported no remaining Citius Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 60,983 Citius Pharmaceuticals shares in Q2 2025, an estimated $90.9K.
  • Squarepoint first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • Squarepoint's Citius Pharmaceuticals position peaked at $330K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.